Physician profile
Anna B Bahnson
NPI 1073177853
$2,297.49
in general payments reported to CMS, 2019-2025
14 companies · $453 in 2025
The $453 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $99.12 · 2023: $1,155 · 2024: $591 · 2025: $453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,118 · Education: $80.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,118.37 |
| Education | $80.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $648.57 | 2023-2025 | Skyrizi, Rinvoq |
| Genzyme Corporation | $389.18 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $223.11 | 2023 | |
| Incyte Corporation | $205.00 | 2023 | Opzelura |
| Boehringer Ingelheim Pharmaceuticals, INC. | $192.66 | 2022-2023 | |
| Janssen Biotech, INC. | $169.55 | 2024-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $133.20 | 2023-2025 | Absorica Ld, Winlevi |
| Regeneron Healthcare Solutions, INC. | $104.80 | 2024-2025 | Dupixent |
| Journey Medical Corporation | $75.93 | 2025 | |
| Galderma Laboratories, L.P. | $72.00 | 2024 | |
| Amgen INC. | $33.44 | 2024-2025 | Otezla |
| Arcutis Biotherapeutics, INC. | $17.48 | 2024 | Zoryve |
| Pfizer INC. | $16.53 | 2025 | |
| Lilly USA, LLC | $16.04 | 2025 | Taltz, Ebglyss |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Bahnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.